181 related articles for article (PubMed ID: 9927611)
1. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.
Khélifa T; Beck WT
Biochem Pharmacol; 1999 Oct; 58(8):1247-57. PubMed ID: 10487526
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
4. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
5. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
6. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic signalling by inhibitors of DNA topoisomerase II.
Beck WT; Mo YY; Bhat UG
Biochem Soc Trans; 2001 Nov; 29(Pt 6):702-3. PubMed ID: 11709058
[TBL] [Abstract][Full Text] [Related]
8. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
9. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
10. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction.
Riffkin CD; Gray AZ; Hawkins CJ; Chow CW; Ashley DM
Neuro Oncol; 2001 Oct; 3(4):229-40. PubMed ID: 11584892
[TBL] [Abstract][Full Text] [Related]
13. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Hirota H; Gosky D; Berger NA; Chatterjee S
Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
[TBL] [Abstract][Full Text] [Related]
14. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
16. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
17. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.
Khélifa T; Beck WT
Mol Pharmacol; 1999 Mar; 55(3):548-56. PubMed ID: 10051540
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
19. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1.
Kasibhatla S; Brunner T; Genestier L; Echeverri F; Mahboubi A; Green DR
Mol Cell; 1998 Mar; 1(4):543-51. PubMed ID: 9660938
[TBL] [Abstract][Full Text] [Related]
20. A novel use for the comet assay: detection of topoisomerase II inhibitors.
Salti GI; Das Gupta TK; Constantinou AI
Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]